(MedPage Today) — The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug’s numerous solid tumors indications.
The new formulation combines pembrolizumab with berahyaluronidase…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/117569
Author :
Publish date : 2025-09-20 15:01:00
Copyright for syndicated content belongs to the linked Source.
